HL7 FHIR Implementation Guide: Breast Cancer Data, Release 1 - US Realm (Draft for Comment 2)

This page is part of the Breast Cancer Data Logical Models and FHIR Profiles (v0.2.0: STU 1 Draft) based on FHIR R3. . For a full list of available versions, see the Directory of published versions

NuclearPleomorphismScoreModel


<StructureDefinition xmlns="http://hl7.org/fhir">
  <id value="oncology-NuclearPleomorphismScore-model"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
  <p><b>BC NuclearPleomorphismScore Logical Model</b></p>
  <p>The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.</p>
</div>
  </text>
  <url
       value="http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-NuclearPleomorphismScore-model"/>
  <identifier>
    <system value="http://hl7.org/fhir/us/breastcancer"/>
    <value value="oncology.NuclearPleomorphismScore"/>
  </identifier>
  <version value="0.2.0"/>
  <name value="NuclearPleomorphismScoreModel"/>
  <title value="BC NuclearPleomorphismScore Logical Model"/>
  <status value="draft"/>
  <date value="2018-08-17T00:00:00+10:00"/>
  <publisher
             value="The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)"/>
  <contact>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/cic/index.cfm"/>
    </telecom>
  </contact>
  <description
               value="The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers."/>
  <keyword>
    <system value="http://loinc.org"/>
    <code value="44645-0"/>
    <display
             value="Nuclear pleomorphism in Breast tumor Qualitative by Nottingham"/>
  </keyword>
  <kind value="logical"/>
  <abstract value="false"/>
  <type value="oncology-NuclearPleomorphismScore-model"/>
  <baseDefinition value="http://hl7.org/fhir/StructureDefinition/Element"/>
  <derivation value="specialization"/>
  <snapshot>
    <element id="oncology-NuclearPleomorphismScore-model">
      <path value="oncology-NuclearPleomorphismScore-model"/>
      <definition
                  value="The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers."/>
      <min value="0"/>
      <max value="*"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model"/>
        <min value="0"/>
        <max value="*"/>
      </base>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.value">
      <path value="oncology-NuclearPleomorphismScore-model.value"/>
      <short
             value="Code representing the degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers."/>
      <definition
                  value="Code representing the degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers."/>
      <min value="1"/>
      <max value="1"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.value"/>
        <min value="1"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <binding>
        <strength value="required"/>
        <valueSetReference>
          <reference value="http://loinc.org/vs/LL4382-9"/>
        </valueSetReference>
      </binding>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.topicCode">
      <path value="oncology-NuclearPleomorphismScore-model.topicCode"/>
      <short
             value="The concept representing the finding or action that is the topic of the statement."/>
      <definition
                  value="The concept representing the finding or action that is the topic of the statement.

For action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the &#39;question&#39; or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.topicCode"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.exceptionValue">
      <path value="oncology-NuclearPleomorphismScore-model.exceptionValue"/>
      <short
             value="Reason that a value associated with a test or other finding is missing."/>
      <definition
                  value="Reason that a value associated with a test or other finding is missing."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.exceptionValue"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <binding>
        <strength value="extensible"/>
        <valueSetReference>
          <reference value="http://hl7.org/fhir/ValueSet/data-absent-reason"/>
        </valueSetReference>
      </binding>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.interpretation">
      <path value="oncology-NuclearPleomorphismScore-model.interpretation"/>
      <code>
        <system value="http://ncimeta.nci.nih.gov"/>
        <code value="C0420833"/>
      </code>
      <short
             value="A clinical interpretation of a finding (applies to both assertions and observation)."/>
      <definition
                  value="A clinical interpretation of a finding (applies to both assertions and observation)."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.interpretation"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <binding>
        <strength value="extensible"/>
        <valueSetReference>
          <reference
                     value="http://hl7.org/fhir/ValueSet/observation-interpretation"/>
        </valueSetReference>
      </binding>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.referenceRange">
      <path value="oncology-NuclearPleomorphismScore-model.referenceRange"/>
      <code>
        <system value="http://ncimeta.nci.nih.gov"/>
        <code value="C0883335"/>
      </code>
      <short value="The usual or acceptable range for a test result."/>
      <definition value="The usual or acceptable range for a test result."/>
      <min value="0"/>
      <max value="0"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.referenceRange"/>
        <min value="0"/>
        <max value="0"/>
      </base>
      <type>
        <code
              value="http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
    </element>
  </snapshot>
  <differential>
    <element id="oncology-NuclearPleomorphismScore-model">
      <path value="oncology-NuclearPleomorphismScore-model"/>
      <definition
                  value="The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers."/>
      <min value="0"/>
      <max value="*"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model"/>
        <min value="0"/>
        <max value="*"/>
      </base>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.value">
      <path value="oncology-NuclearPleomorphismScore-model.value"/>
      <short
             value="Code representing the degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers."/>
      <definition
                  value="Code representing the degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers."/>
      <min value="1"/>
      <max value="1"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.value"/>
        <min value="1"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <binding>
        <strength value="required"/>
        <valueSetReference>
          <reference value="http://loinc.org/vs/LL4382-9"/>
        </valueSetReference>
      </binding>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.topicCode">
      <path value="oncology-NuclearPleomorphismScore-model.topicCode"/>
      <short
             value="The concept representing the finding or action that is the topic of the statement."/>
      <definition
                  value="The concept representing the finding or action that is the topic of the statement.

For action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the &#39;question&#39; or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.topicCode"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.exceptionValue">
      <path value="oncology-NuclearPleomorphismScore-model.exceptionValue"/>
      <short
             value="Reason that a value associated with a test or other finding is missing."/>
      <definition
                  value="Reason that a value associated with a test or other finding is missing."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.exceptionValue"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <binding>
        <strength value="extensible"/>
        <valueSetReference>
          <reference value="http://hl7.org/fhir/ValueSet/data-absent-reason"/>
        </valueSetReference>
      </binding>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.interpretation">
      <path value="oncology-NuclearPleomorphismScore-model.interpretation"/>
      <code>
        <system value="http://ncimeta.nci.nih.gov"/>
        <code value="C0420833"/>
      </code>
      <short
             value="A clinical interpretation of a finding (applies to both assertions and observation)."/>
      <definition
                  value="A clinical interpretation of a finding (applies to both assertions and observation)."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.interpretation"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <binding>
        <strength value="extensible"/>
        <valueSetReference>
          <reference
                     value="http://hl7.org/fhir/ValueSet/observation-interpretation"/>
        </valueSetReference>
      </binding>
    </element>
    <element id="oncology-NuclearPleomorphismScore-model.referenceRange">
      <path value="oncology-NuclearPleomorphismScore-model.referenceRange"/>
      <code>
        <system value="http://ncimeta.nci.nih.gov"/>
        <code value="C0883335"/>
      </code>
      <short value="The usual or acceptable range for a test result."/>
      <definition value="The usual or acceptable range for a test result."/>
      <min value="0"/>
      <max value="0"/>
      <base>
        <path value="oncology-NuclearPleomorphismScore-model.referenceRange"/>
        <min value="0"/>
        <max value="0"/>
      </base>
      <type>
        <code
              value="http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model"/>
      </type>
      <mustSupport value="false"/>
      <isModifier value="false"/>
      <isSummary value="false"/>
    </element>
  </differential>
</StructureDefinition>